1. Create your account. Register with your name and email, verify your email using the code you receive, then sign in. The animation uses fictional account details and shortened timing.

2. Ask your question. From Home, enter: “What are the latest news in non-small cell lung cancer?”

The following answer was supplied for this demonstration and has not been independently verified. It is not a live news feed or a treatment recommendation. Citation markers are retained; source URLs were not supplied.

The most recent NSCLC-specific developments in the supplied news sources are FDA actions in HER2-mutant non-squamous NSCLC, ROS1-positive NSCLC, and a tumor-agnostic approval relevant to RET fusion–positive NSCLC. These reports describe regulatory decisions and the single-arm clinical studies supporting them; they should not be interpreted as comparative trials or as clinical-guideline recommendations. [1][2][3][4]

1. HER2 (ERBB2) tyrosine-kinase-domain activating mutations: two 2026 FDA accelerated approvals

Clinical interpretation of the HER2 developments

• Sevabertinib’s September 2026 action expanded a prior accelerated approval that had been restricted to patients after prior systemic therapy, according to the FDA report. [1]
• Both reports concern an overlapping biomarker-defined setting—advanced non-squamous NSCLC with HER2/ERBB2 TKD activating mutations—and both supporting efficacy analyses used open-label, multicenter, single-arm studies with confirmed ORR and duration of response assessed by blinded independent central review using RECIST v1.1. [1][4]
• The reported ORRs are numerically similar—75% for sevabertinib and 76% for zongertinib—but the supplied evidence does not provide a head-to-head comparison, randomized comparison, or information establishing relative efficacy between the two agents. [1][4]
• Dosing differs: sevabertinib is reported as 20 mg orally twice daily with food, whereas zongertinib is 120 mg once daily for patients <90 kg and 180 mg once daily for patients ≥90 kg, with or without food. [1][4]

2. ROS1-positive NSCLC after prior ROS1 TKI therapy: zidesamtinib approval

• On July 22, 2026, the FDA approved zidesamtinib (Jideytro) for adults with locally advanced or metastatic ROS1-positive NSCLC who had received at least one prior ROS1 tyrosine kinase inhibitor (TKI). [2]
• The approval was supported by ARROS-1, a multicenter, open-label, single-arm, multi-cohort study in previously treated ROS1-positive locally advanced or metastatic NSCLC. [2]
• Across 117 patients, the blinded independent central review-assessed ORR was 44% (95% CI, 34–53); 82% of responders had a duration of response of at least 6 months and 69% had a duration of response of at least 12 months. [2]
• The reported ORR was 49% (95% CI, 36–63) among patients with one prior ROS1 TKI and 38% (95% CI, 26–52) among those with two or more prior ROS1 TKIs, including lorlatinib, repotrectinib, and/or taletrectinib. [2]
• Key labeled warnings and precautions include CNS adverse reactions, QTc prolongation, ILD/pneumonitis, skeletal fractures, myalgia with creatine phosphokinase elevation, pancreatic toxicity, and embryo-fetal toxicity; the reported recommended dose is 100 mg orally once daily, with or without food. [2]

3. RET fusion–positive disease: traditional tumor-agnostic approval with NSCLC relevance

• On July 14, 2026, the FDA granted traditional approval to selpercatinib (Retevmo) for adults and pediatric patients aged 2 years or older with locally advanced or metastatic RET fusion–positive solid tumors, detected by an FDA-approved test, after progression on or following prior systemic treatment or when no satisfactory alternatives exist. [3]
• This was a conversion from prior accelerated approvals for the tumor-agnostic indication: adult accelerated approval in 2022 and pediatric accelerated approval in 2024. [3]
• The FDA report states that the evidence base included LIBRETTO-001 and was supported by results in RET fusion–positive NSCLC and RET fusion–positive thyroid cancer. [3]
• In the reported group of 75 patients with RET fusion–positive tumors other than NSCLC and thyroid cancer, ORR was 47% (95% CI, 35–59) and median duration of response was 24.5 months (95% CI, 11.2–49.1); these numerical outcomes should not be treated as NSCLC-specific results because that cohort excluded NSCLC. [3]
• Label warnings include hepatotoxicity, ILD/pneumonitis, hypertension, QT prolongation, hemorrhagic events, hypersensitivity, tumor-lysis syndrome, impaired wound healing, hypothyroidism, embryo-fetal toxicity, and a pediatric warning for slipped capital/upper femoral epiphysis. [3]

4. RAS/KRAS research context relevant to NSCLC

• An NCI research-news report dated October 8, 2026 describes the broader progress in targeting mutant RAS proteins, including the FDA approval of sotorasib in May 2021 and accelerated approval of adagrasib in December 2022 for KRAS G12C–mutant NSCLC. [0]
• The same NCI report describes RAS mutations as contributing to approximately one-third of cancers and notes that KRAS is reported as involved in up to 30% of lung cancer cases. [0]
• The report also notes development of broader-acting RAS inhibitors, including daraxonrasib, and NCI-linked investigational compounds BBO-8520, BBO-11818, and BBO-10203; however, the supplied material does not provide NSCLC-specific trial results, regulatory approvals, or detailed clinical outcomes for these agents. [0]

Evidence strengths and limitations across the updates

• The new HER2- and ROS1-directed decisions were supported by single-arm clinical trials using ORR and duration of response as major efficacy measures, rather than by randomized comparative data described in the supplied reports. [1][2][4]
• The HER2 approvals are explicitly accelerated approvals, whereas selpercatinib’s July 2026 tumor-agnostic RET fusion indication received traditional approval. [1][3][4]
• Molecular testing is central to each relevant indication: the HER2 and RET reports specify testing by FDA-authorized or FDA-approved assays, respectively, while the ROS1 report identifies ROS1-positive disease but does not specify in the supplied text that an FDA-authorized assay is required. [1][2][3][4]
• The supplied references do not specify optimal sequencing between sevabertinib and zongertinib, comparative activity against one another, resistance mechanisms, survival outcomes, central-nervous-system efficacy, or guideline placement for these treatments.